

# INTERIM REPORT FOR 1ST QUARTER ENDED 31 MARCH 2018



#### 8<sup>th</sup> Floor, Wisma Naim, 2<sup>1</sup>/<sub>2</sub> Mile Rock Road, 93200 Kuching, Sarawak, Malaysia

Facsimile No: 082-256650

Email: info@spbgroup.com.my

### INTERIM REPORT FOR THE FIRST QUARTER ENDED 31 MARCH 2018 (The figures have not been unaudited)

#### Page

Condensed Consolidated Statement of Financial Position	1 – 2
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	3 – 4
Condensed Consolidated Statement of Changes in Equity	5 – 6
Condensed Consolidated Statement of Cash Flows	7 – 8

#### **Explanatory Notes**

Telephone No: 082-233550

Part A – Explanatory Notes Pursuant to MFRS 134	9-21
Part B – Explanatory Notes Pursuant to Part A of Appendix 9B of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities")	22– 27



#### Condensed Consolidated Statement of Financial Position

(The figures have not been audited)

Notes	As At End Of Current Financial Period 31/3/2018 (Unaudited) RM'000	As At End Of Preceding Financial Year 31/12/2017 Restated RM'000	As At End Of Preceding Financial Year 1/1/2017 Restated RM'000
ASSETS			
Non-current assets			
Property, plant and equipment	372,178	369,364	384,586
Plantation development expenditure	288,825	287,890	285,303
Investment properties	4,330	4,455	4,621
Total non-current assets	665,333	661,709	674,510
Current assets			
Inventories	16,051	16,975	18,092
Biological Assets	26,930	24,707	37,184
Trade and other receivables	9,345	22,392	24,700
Prepayments and other assets	4,566	4,448	4,593
Current tax recoverable	8,407	3,306	156
Other investments B6	9,626	9,678	9,466
Cash and cash equivalents	105,188	104,400	100,397
	180,113	185,906	194,588
Assets classified as held for sale	949	949	949
Total current assets	181,062	186,855	195,537
TOTAL ASSETS	846,395	848,564	870,047



#### Condensed Consolidated Statement of Financial Position (continued)

(The figures have not been audited)

	Notes	As At End Of Current Financial Period 31/3/2018 (Unaudited) RM'000	As At End Of Preceding Financial Year 31/12/2017 Restated RM'000	As At End Of Preceding Financial Year 1/1/2017 Restated RM'000
EQUITY AND LIABILITIES				
Equity				
Share capital	A5	340,969	340,969	280,000
Share premium		-	-	60,969
Reserves		206,253	207,989	201,685
Equity attributable to Owners of the Company		547,222	548,958	542,654
Non-controlling interests		(10,161)	(10,102)	(9,844)
Total equity		537,061	538,856	532,810
Non-current liabilities				
Deferred tax liabilities		113,533	114,089	117,362
Loans and borrowings	B7	106,151	110,291	89,943
Total non-current liabilities		219,684	224,380	207,305
Current liabilities				
Trade and other payables		50,122	55,720	86,991
Loans and borrowings	B7	39,495	29,577	42,925
Current tax payable		33	31	16
Total current liabilities		89,650	85,328	129,932
Total liabilities		309,334	309,708	337,237
TOTAL EQUITY AND LIABILITIES		846,395	848,564	870,047
Net assets per share attributable to Owners of the Company (RM)		1.96	1.96	1.94

(The Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2017 and the accompanying explanatory notes attached to this report)



# Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (The figures have not been audited)

		Individual C	Quarter (Q1)		ive Quarter onths)
		Current Year Quarter 31/3/2018	Preceding Year Corresponding Quarter (Restated) 31/3/2017	Current Year - Period To Date 31/3/2018	Preceding Year - Period To Date (Restated) 31/3/2017
	Notes	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited
		RM'000	RM'000	RM'000	RM'000
Revenue		70,936	109,631	70,936	109,63 <sup>2</sup>
Cost of sales		(66,625)	(81,430)	(66,625)	(81,430
Gross profit	-	4,311	28,201	4,311	28,207
Other income		538	322	538	322
Distribution expenses		(3,798)	(5,533)	(3,798)	(5,533
Administrative expenses		(4,149)	(4,054)	(4,149)	(4,054
Results from operating act	ivities	(3,098)	18,936	(3,098)	18,93
Finance income		860	760	860	760
Finance costs		(1,634)	(1,438)	(1,634)	(1,438
Net finance costs		(774)	(678)	(774)	(678
Operating (loss)/profit befo	ore tax	(3,872)	18,258	(3,872)	18,25
Change in fair value of biological assets		2,223	(4,977)	2,223	(4,977
(Loss)/Profit before tax	A15	(1,649)	13,281	(1,649)	13,28
Taxation	B5	(146)	(3,323)	(146)	(3,323
(Loss)/Profit after tax	-	(1,795)	9,958	(1,795)	9,95
Other comprehensive inco net of tax	me,	-	-	-	
(Loss)/Profit and total comprehensive (loss)/inco for the period	me	(1,795)	9,958	(1,795)	9,95



### Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (continued) (The figures have not been audited)

		Individual	Quarter (Q1)		ve Quarter onths)
		Current Year Quarter 31/3/2018	Preceding Year Corresponding Quarter (Restated) 31/3/2017	Current Year - Period To Date 31/3/2018	Preceding Year - Period To Date (Restated) 31/3/2017
	Notes	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited
		RM'000	RM'000	RM'000	RM'000
(Loss)/Profit attributable to:					
Owners of the Company		(1,736)	9,990	(1,736)	9,990
Non-controlling interests		(59)	(32)	(59)	(32)
(Loss)/Profit for the period		(1,795)	9,958	(1,795)	9,958
(Loss)/Profit and total comprehensive (loss)/incom attributable to:	e				
Owners of the Company		(1,736)	9,990	(1,736)	9,990
Non-controlling interests		(59)	(32)	(59)	(32)
(Loss)/Profit and total comprehensive (loss)/incom the period	e for	(1,795)	9,958	(1,795)	9,958
Basic (loss)/earnings per orc share attributable to Owners Company (sen):					
Basic	B12	(0.62)	3.57	(0.62)	3.57
Diluted	B12	N/A	N/A	N/A	N/A

(The Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2017 and the accompanying explanatory notes attached to this report)



#### Condensed Consolidated Statement of Changes in Equity

(The figures have not been audited)

		Attribu	table to Owner	s of the Comp	any			
	-	No	n-distributable		Distributable			
	Notes	Share capital RM'000	Equity reserve RM'000	Treasury shares RM'000	Retained earnings RM'000	Total RM'000	Non- controlling interests RM'000	Total equity RM'000
At 1 January 2018		340,969	493	(1,223)	288,340	628,579	(10,102)	618,477
Effect of MFRS adoption and changes in accounting policies	_	-	-	-	(79,621)	(79,621)	-	(79,621)
At 1 January 2018, restated		340,969	493	(1,223)	208,719	548,958	(10,102)	538,856
Loss and total comprehensive loss for the period		-	-	-	(1,736)	(1,736)	(59)	(1,795)
At 31 March 2018		340,969	493	(1,223)	206,983	547,222	(10,161)	537,061

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2017 and the accompanying explanatory notes attached to this report)



#### **Condensed Consolidated Statement of Changes in Equity**

(The figures have not been audited)

			Attributable to	Owners of the	e Company				
	-		Non-distribu	utable		Distributable			
	Notes	Share capital RM'000	Share premium RM'000	Equity reserve RM'000	Treasury shares RM'000	Retained earnings RM'000	Total RM'000	Non- controlling interests RM'000	Total equity RM'000
At 1 January 2017		280,000	60,969	493	(1,223)	298,592	638,831	(9,844)	628,987
Effect of MFRS adoption and changes in accounting policies	-	-	-	-	-	(96,177)	(96,177)	-	(96,177)
At 1 January 2017, restated		280,000	60,969	493	(1,223)	202,415	542,654	(9,844)	532,810
Transfer in accordance with Section 618(2) of the Companies Act 2016		60,969	(60,969)	-	-	-	-	-	-
Profit and total comprehensive Profit for the period		-	-	-	-	9,990	9,990	(32)	9,958
At 31 March 2017, restated		340,969	-	493	(1,223)	212,405	552,644	(9,876)	542,768

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2017 and the accompanying explanatory notes attached to this report)



# **Condensed Consolidated Statement of Cash Flows** (The figures have not been audited)

	Cumulative Quarter (3 Months)		
	Current Year - Period To Date	Preceding Year - Period To Date	
	31/3/2018	31/3/201 (restated	
	(unaudited)	(Unaudited)	
	RM'000	RM'000	
Cash flows from operating activities			
(Loss)/Profit before tax	(1,649)	13,281	
Adjustments for:			
Change in fair value of other investments	111	(52)	
Change in fair value of biological assets	(2,223)	4,977	
Depreciation of property, plant and equipment	6,028	6,057	
Depreciation of plantation development expenditure	3,695	4,065	
Depreciation of investment properties	42	42	
Dividend income from other investments	(41)	(35)	
Gain on disposal of:			
- other investments	(9)	(20)	
Inventories written off	70	-	
Finance income	(860)	(760)	
Finance costs	1,634	1,438	
Operating profit before changes in working capital	6,798	28,993	
Change in inventories	855	4,482	
Change in trade and other receivables, deposits and prepayments	11,882	9,969	
Change in trade and other payables	(11,575)	(19,740)	
Cash generated from operations	7,960	23,704	
Tax paid	(4,882)	(940)	
Interest/Profit paid	(1,608)	(1,464)	
Finance lease profit paid	(27)	(45)	
Interest received	986	721	
Net cash from operating activities	2,429	21,976	
Cash flows from investing activities			
Acquisition of property, plant and equipment	(2,026)	(13,206)	
Dividend received	35	29	
Net movement of deposits with original maturities exceeding three months	(41)	(826)	
Plantation development expenditure (net of depreciation)	(3,123)	(20,899)	
Net cash used in investing activities	(5,155)	(34,902)	



#### Condensed Consolidated Statement of Cash Flows (continued)

(The figures have not been audited)

	Cumulative Qua	arter (3 Months)										
	Current Year - Period To Date	Preceding Year - Period To Date										
	31/3/2018			31/3/2018	31/3/2018							31/3/2017 (restated)
	(Unaudited)	(Audited)										
	RM'000	RM'000										
Cash flows from financing activities												
Net proceeds from term loans and revolving credits	4,010	18,100										
Repayment of finance lease liabilities	(496)	-										
Net cash from financing activities	3,514	18,100										
Net increase in cash and cash equivalents	788	5,174										
Cash and cash equivalents as at 1 January	104,400	100,397										
Cash and cash equivalents as at 31 March	105,188	105,571										
Represented by:												
Deposits with original maturities not exceeding three months	84,005	105,390										
Cash and bank balances	21,183	181										
Cash and cash equivalents	105,188	105,571										

(The Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2017 and the accompanying notes attached to this report)



#### Part A – Explanatory Notes Pursuant to Malaysian Financial Reporting Standards ("MFRS") 134

#### A1. Basis of preparation

#### 1. Statement of compliance

The condensed consolidated interim financial statements of the Group are unaudited and have been prepared in accordance with the requirements of Malaysian Financial Reporting Standard ("MFRS") 134, *Interim Financial Reporting* and Chapter 9, Part K of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities").

The condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2017.

#### 2. Significant accounting policies

#### 2.1 Adoption of new/revised Standards, Amendments and Interpretations

The Group's financial statements for annual period beginning on 1 January 2018 is prepared in accordance with the Malaysian Financial Reporting Standards ("MFRSs") issued by the MASB.

The Group adopted following accounting standards, amendments and interpretations where applicable:

#### Standards / Amendments / Interpretations

MFRS 1	
MFRS 2	
MFRS 3	Business Combinations
MFRS 4	
MFRS 5	
MFRS 7	Mandatory Effective Date of MFRS 9 and Transition Disclosures
MFRS 8	Operating Segments
MFRS 9	MFRS 9, Financial Instruments (2014)
MFRS 10	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments to MFRS 10 and MFRS 128)



A1.	Basis of	preparation	(continued)
~	Busis of	propulation	(continued)

- 2.
- Significant accounting policies (continued) Adoption of new/revised Standards, Amendments and Interpretations (continued) 2.1

#### Standards / Amendments / Interpretations

MFRS 11	<ul> <li>Joint Arrangements</li> <li>Accounting for Acquisitions of Interests in Joint Operations (Amendments to MFRS 11)</li> </ul>
MFRS 12	<ul> <li>Disclosure of Interests in Other Entities</li> <li>Investment Entities: Applying the Consolidation Exception (Amendments to MFRS 10, MFRS 12 and MFRS 128)</li> <li>Amendments to MFRS 12 Disclosure of Interests in Other Entities (Annual Improvements to MFRS Standards 2014-2016 Cycle)</li> </ul>
MFRS 13	Fair Value Measurement
MFRS 14	Regulatory Deferral Accounts
MFRS 15	<ul><li>Revenue from Contracts with Customers</li><li>Classification as to MFRS 15</li></ul>
MPRS 101	<ul> <li>Presentation of Financial Statements</li> <li>Disclosure Initiative (Amendments to MFRS 101)</li> </ul>
MFRS 102	Inventories
MFRS 107	<ul><li>Statement of Cash Flows</li><li>Disclosure Initiative (Amendments to MFRS 107)</li></ul>
MFRS 108	Accounting Policies, Changes in Accounting Estimates and Errors
MFRS 110	Event after the Reporting Period
MFRS 112	<ul> <li>Income Taxes</li> <li>Recognition of Deferred Tax Assets for Unrealised Losses (Amendments to MFRS 112)</li> </ul>
MFRS 116	<ul> <li>Property, Plant and Equipment</li> <li>Clarification of Acceptable Methods of Depreciation and Amortisation (Amendments to MFRS 116 and MFRS 138)</li> <li>Agriculture: Bearer Plants (Amendments to MFRS 116 and MFRS 141)</li> </ul>
MFRS 117	• Leases
MFRS 123	Borrowing Costs
MFRS 124	Related Party Disclosures
MFRS 127	<ul> <li>Separate Financial Statements</li> <li>Equity Method in Separate Financial Statements (Amendments to MFRS 127)</li> </ul>



#### A1. Basis of preparation (continued)

- 2. Significant accounting policies (continued)
- 2.1 Adoption of new/revised Standards, Amendments and Interpretations (continued)

#### Standards / Amendments / Interpretations

MFRS 128	<ul> <li>Investments in Associates and Joint Ventures</li> <li>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments to MFRS 10 and MFRS 128)</li> <li>Investment Entities: Applying the Consolidation Exception (Amendments to MFRS 10, MFRS 12 and MFRS 128)</li> <li>Investments in Associates and Joint Ventures (Annual Improvements to MFRS Standards 2014-2016 Cycle)</li> </ul>
MFRS 132	Financial Instruments: Presentation
MFRS 133	Earnings per Share
MFRS 134	<ul> <li>Interim Financial Reporting</li> <li>Amendment to MFRS 134, Interim Financial Reporting (Annual Improvements to MFRSs 2012–2014 Cycle)</li> </ul>
MFRS 136	Impairment of Assets
MFRS 137	Provisions, Contingent Liabilities and Contingent Assets
MFRS 138	<ul> <li>Intangible Assets</li> <li>Clarification of Acceptable Methods of Depreciation and Amortisation (Amendments to MFRS 116 and MFRS 138)</li> </ul>
MFRS 139	Financial Instruments: Recognition and Measurement
MFRS 140	<ul> <li>Investment Property</li> <li>Transfers of Investment Property (Amendments to MFRS 140)</li> </ul>
MFRS 141	<ul> <li>Agriculture</li> <li>Agriculture: Bearer Plants (Amendments to MFRS 116 and MFRS 141)</li> </ul>

### 2.2 Financial effect arising from the adoption of Amendments to MFRS 116, *Property, Plant and Equipment* and MFRS 141, *Agriculture - Agriculture: Bearer Plants*

Accordingly, the financial statements for the previous financial period and years have been revised as follows:



#### A1. Basis of preparation (continued)

- 2. Significant accounting policies (continued)
- 2.2 Financial effect arising from the adoption of Amendments to MFRS 116, Property, Plant and Equipment and MFRS 141, Agriculture Agriculture: Bearer Plants (continued)

#### (a) Condensed Consolidated Statement of Financial Position

	As previously reported	Effect of adoption of MFRS 141	Restated
	RM'000	RM'000	RM'000
As at 1/1/2017			
Property, plant and equipment	384,586	-	384,586
Plantation development expenditure	354,742	(69,439)	285,303
Biological Assets	-	37,184	37,184
Reserves	297,862	(96,177)	201,685
Deferred tax liabilities	53,440	63,922	117,362
As at 31/12/2017			
Property, plant and equipment	368,092	1,272	369,364
Plantation development expenditure	330,734	(42,844)	287,890
Biological Assets	-	24,707	24,707
Reserves	287,610	(79,621)	207,989
Deferred tax liabilities	51,333	62,756	114,089

#### (b) Statement of profit or loss and other comprehensive income

	As previously	Effect of adoption	
	reported	of MFRS 141	Restated
	RM'000	RM'000	RM'000
Period ended 31/3/2017			
Cost of sales	(77,420)	(4,010)	(81,430)
Fair value of biological assets	-	(4,977)	(4,977)
Replanting expenditure	(5,052)	5,052	-
Taxation	(4,061)	738	(3,323)
Profit for the period	13,155	(3,197)	9,958
Year ended 31/12/2017			
Cost of sales	(301,427)	(16,037)	(317,464)
Fair value of biological assets	-	(12,477)	(12,477)
Replanting expenditure	(13,387)	13,387	-
Other non-operating expenses	(43,408)	30,517	(12,891)
Taxation	(8,964)	1,167	(7,797)
(Loss)/Profit for the year	(10,510)	16,555	6,045



#### A1. Basis of preparation (continued)

#### 2. Significant accounting policies (continued)

#### 2.3 Financial effect arising from the adoption of MFRS 9, *Financial Instruments*

MFRS 9 replaces the guidance in FRS 139, *Financial Instruments: Recognition and Measurement* on the classification and measurement of financial assets and financial liabilities, and on hedge accounting.

There are no material financial impacts on the financial statements for the current financial period and past years upon initial application of MFRS 9.

### 2.4 Financial effect arising from the adoption of MFRS 15, *Revenue from Contracts with Customers and Clarifications to MFRS 15, Revenue from Contracts with Customers*

MFRS 15 replaces the guidance in MFRS 111, *Construction Contracts*, MFRS 118, *Revenue*, IC Interpretation 13, *Customer Loyalty Programmes*, IC Interpretation 15, *Agreements for Construction of Real Estate*, IC Interpretation 18, *Transfers of Assets from Customers* and IC Interpretation 131, *Revenue – Barter Transactions Involving Advertising Services.* 

The Group recognised revenue from contracts with customers in accordance with the accounting policies as described in Note 2(m) of the financial statements for the financial year ended 31 December 2017. Upon adoption of MFRS 15, the Group recognises the revenue from contracts with customers when the Group transfers controls of goods or services to its customers at the amount to which the Group expects to entitled. Revenue is recognised over time or at a point in time, when control of goods or services is transferred to the customers.

There are no material financial impacts on the financial statements for the current financial period and past years upon initial application of MFRS 15.

#### 2.5 Standards issued but not yet effective

Standards / Amendments / Interpretations	Effective date
MFRS 16, Leases	1 January 2019
IC Interpretation 23, Uncertainty over Income Tax Treatments	1 January 2019
Amendments to MFRS 3, Business Combinations (Annual Improvements to MFRS Standards 2015 – 2017 Cycle)	1 January 2019
Amendments to MFRS 9, <i>Financial Instruments</i> (2014) <ul> <li>Prepayment Features with Negative Compensation</li> </ul>	1 January 2019
Amendments to MFRS 112, Income Taxes (Annual Improvements to MFRS Standards 2015 – 2017 Cycle)	1 January 2019
Amendments to MFRS 123, Borrowing Costs (Annual Improvements to MFRS Standards 2015 – 2017 Cycle)	1 January 2019
Amendments to MFRS 128, Investment in Associates and Joint Ventures – Long-term Interest in Associates and Joint Ventures	1 January 2019



A1.	Basis	of	preparation	(continued)	
~!.	Dusis	<b>U</b> I	proparation	(continucu)	

2.	Significant accounting policies (continued)
0 F	Otom dowed a foreign built wat uset affectives (a sufficiently

2.5 Standards issues but not yet effective (continued)

Standards / Amendments / Interpretations	Effective date
Amendments to MFRS 11, Joint Arrangements (Annual Improvements to MFRS Standards 2015-2017 Cycle)	1 January 2019
Amendments to MFRS 3, Business Combinations	1 January 2020
Amendments to MFRS 2, Share-based Payment	1 January 2020
Amendments to MFRS 14, Regulatory Deferral Accounts	1 January 2020
Amendments to MFRS 101, Presentation of Financial Statements	1 January 2020
Amendments to MFRS 108, Accounting Policies, Changes in Accounting Estimates and Errors	1 January 2020
Amendment to MFRS 134 Interim Financial Reporting	1 January 2020
Amendment to MFRS 137, <i>Provisions, Contingent Liabilities and Contingent Assets</i>	1 January 2020
Amendment to MFRS 138, Intangible Assets	1 January 2020

The Group will adopt the above when they become effective in the respective financial periods.

Material impacts of the initial application of the abovementioned accounting standards, amendments or interpretations, which are or likely to be applicable to the Group, are discussed below:

#### (i) MFRS 16, *Leases*

MFRS 16 replaces the guidance in MFRS 117, *Lease*, IC Interpretation 4, *Determining Whether an Arrangement contains a Lease*, IC Interpretation 115, *Operating Leases – Incentives* and IC Interpretation 127, *Evaluating the Substance of Transactions Involving the Legal Form of a Lease*.

The Group is currently assessing the financial impact that may arise from the adoption of MFRS 16.

### (ii) Amendment to MFRS 128, Investment in Associates and Joint Ventures (Annual Improvements to MFRS Standards 2014 – 2016 Cycle)

The amendments clarify that an entity, which is a venture capital organization, or a mutual fund, unit trust or similar entities, has an investment-by-investment choice to measure its investments in associates and joint ventures at fair value.

There will be no significant impact on the Group from the adoption of Amendments to MFRS 128.



#### A2. Seasonality or Cyclicality of Interim Operations

The Group's performance is affected by the cropping pattern of fresh fruit bunches ("FFB") which normally reaches its peak in the second half of the year, that will be reflected accordingly in the crude palm oil ("CPO") and palm kernel ("PK") production of the Group. The performance is also affected by the prices of CPO and PK which are determined by global supply and demand situation for edible oils and fats.

#### A3. Unusual Items Affecting Assets, Liabilities, Equity, Net income or Cash Flows

There were no items affecting assets, liabilities, equity, net income, or cash flows, which were unusual in nature, size or incidence during the current financial period.

#### A4. Material Changes in Estimates

There were no changes in the estimates of amounts reported in prior financial years and preceding interim periods, which have a material effect in the current interim financial period.

A5. Issuances, Cancellations, Repurchases, Resale and Repayments of Debt and Equity Securities There were no issuances, cancellations, repurchases, resale and repayments of debt and equity in the current interim financial period.

#### A6. Dividends Paid

There was no dividend paid during the current interim financial period.

#### A7. Segment Information

The Group's business segments mainly comprise the following three major business segments:-

#### (i) Investment holding

Investment holding company

#### (ii) Oil palm operations

- Estate operations (Cultivation of oil palm)

- Mill operations (processing of fresh fruit bunches)

#### (iii) Management services and rental

Provision of management service and rental of investment properties



#### A7. Segment Information (continued)

	Investment holding	Management services and rental	Oi	I palm operatio	ons	Consolidated
31/3/2018	RM'000	RM'000	Estate operations RM'000	Mill operations RM'000	Total RM'000	RM'000
Revenue						
Segment revenue	-	973	21,585	68,442	90,027	91,000
Inter-segment	-	(767)	-	-	(19,297)	(20,064)
External revenue	-	206	21,585	68,442	70,730	70,936
<b>Cost of sales</b> Segment cost of sales	-	(489)	(22,921)	(62,578)	(85,499)	(85,988)
Inter-segment	-	45	-	-	19,318	19,363
External cost of sales	-	(444)	(22,921)	(62,578)	(66,181)	(66,625)
Gross profit/(loss)	-	(238)	(1,336)	5,864	4,549	4,311
Distribution expenses	-	-	-	(3,798)	(3,798)	(3,798)
Profit/(Loss)	-	(238)	(1,336)	2,066	751	513
Other income including finance income	683	223			725	1,631
Inter-segment	(63)	(3)			(167)	(233)
External other income	620	220			558	1,398
Other expenses including finance costs	(675)	(500)			(5,428)	(6,603)
Inter-segment	96	150			574	820
External other expenses	(579)	(350)			(4,854)	(5,783)
Operating profit /(loss) before tax	41	(368)			(3,545)	(3,872)
Change in fair value of biological assets	-	-			2,223	2,223
Profit /(Loss) before tax	41	(368)			(1,322)	(1,649)



#### A7. Segment Information (continued)

#### Individual Quarter (Q1) / Cumulative Quarter (3 Months)

Revenue         985         109,398         110,383           Inter-segment revenue         -         (752)         -         (752)           External revenue         -         233         109,398         109,631           Cost of sales         -         (465)         (81,019)         (81,484)           Inter-segment cost of sales         -         45         9         54           External cost of sales         -         (420)         (81,010)         (81,430)           Inter-segment cost of sales         -         (187)         28,358         28,201           Other income including finance income         595         182         668         1,445           Inter-segment         (466)         (4)         (313)         (363)           External other income         549         178         355         1,082           Other expenses including finance costs         (745)         (315)         (10,863)         (12,073)           Inter-segment         96         176         626         898           External other expenses         (649)         (139)         (10,237)         (11,175)           Operating (loss)/profit before tax         (100)         (148)         18,506	31/03/2017 (restated)	Investment holding RM'000	Management services, rental and others RM'000	Oil palm operations RM'000	Consolidated RM'000
Inter-segment revenue         -         (752)         -         (752)           External revenue         -         233         109,398         109,631           Cost of sales         -         (465)         (81,019)         (81,484)           Inter-segment cost of sales         -         45         9         54           External cost of sales         -         (420)         (81,010)         (81,430)           Gross (loss)/profit         -         (187)         28,358         28,201           Other income including finance income         595         182         668         1,445           Inter-segment         (46)         (4)         (313)         (363)           External other income         549         178         355         1,082           Other expenses including finance costs         (745)         (315)         (10,863)         (12,073)           Inter-segment         96         176         626         898           External other expenses         (649)         (139)         (10,237)         (11,175)           Operating (loss)/profit before tax         (100)         (148)         18,506         18,258           Change in fair value of biological assets         -         - </th <th>Revenue</th> <th></th> <th></th> <th></th> <th></th>	Revenue				
External revenue         -         233         109,398         109,631           Cost of sales         Segment cost of sales         -         (465)         (81,019)         (81,484)           Inter-segment cost of sales         -         45         9         54           External cost of sales         -         (420)         (81,010)         (81,430)           Gross (loss)/profit         -         (187)         28,358         28,201           Other income including finance income         595         182         668         1,445           Inter-segment         (46)         (4)         (313)         (363)           External other income         549         178         355         1,082           Other expenses including finance costs         (745)         (315)         (10,863)         (12,073)           Inter-segment         96         176         626         898           External other expenses         (649)         (139)         (10,237)         (11,175)           Operating (loss)/profit before tax         (100)         (148)         18,506         18,258           Change in fair value of biological assets         -         -         (4,977)         (4,977)	Segment revenue	-	985	109,398	110,383
Cost of sales         -         (465)         (81,019)         (81,484)           Inter-segment cost of sales         -         45         9         54           External cost of sales         -         (420)         (81,010)         (81,430)           Gross (loss)/profit         -         (187)         28,358         28,201           Other income including finance income         595         182         668         1,445           Inter-segment         (46)         (4)         (313)         (363)           External other income         549         178         355         1,082           Other expenses including finance costs         (745)         (315)         (10,863)         (12,073)           Inter-segment         96         176         626         898           External other expenses         (649)         (139)         (10,237)         (11,175)           Operating (loss)/profit before tax         (100)         (148)         18,506         18,258           Change in fair value of biological assets         -         -         (4,977)         (4,977)	Inter-segment revenue	-	(752)	-	(752)
Segment cost of sales         -         (465)         (81,019)         (81,484)           Inter-segment cost of sales         -         45         9         54           External cost of sales         -         (420)         (81,010)         (81,430)           Gross (loss)/profit         -         (187)         28,358         28,201           Other income including finance income         595         182         668         1,445           Inter-segment         (46)         (4)         (313)         (363)           External other income         549         178         355         1,082           Other expenses including finance costs         (745)         (315)         (10,863)         (12,073)           Inter-segment         96         176         626         898           External other expenses         (649)         (139)         (10,237)         (11,175)           Operating (loss)/profit before tax         (100)         (148)         18,506         18,258           Change in fair value of biological assets         -         -         (4,977)         (4,977)	External revenue	-	233	109,398	109,631
Inter-segment cost of sales         -         45         9         54           External cost of sales         -         (420)         (81,010)         (81,430)           Gross (loss)/profit         -         (187)         28,358         28,201           Other income including finance income         595         182         668         1,445           Inter-segment         (46)         (4)         (313)         (363)           External other income         549         178         355         1,082           Other expenses including finance costs         (745)         (315)         (10,863)         (12,073)           Inter-segment         96         176         626         898           External other expenses         (649)         (139)         (10,237)         (11,175)           Operating (loss)/profit before tax         (100)         (148)         18,506         18,258           Change in fair value of biological assets         -         -         (4,977)         (4,977)	- Cost of sales				
External cost of sales         -         (420)         (81,010)         (81,430)           Gross (loss)/profit         -         (187)         28,358         28,201           Other income including finance income         595         182         668         1,445           Inter-segment         (46)         (4)         (313)         (363)           External other income         549         178         355         1,082           Other expenses including finance costs         (745)         (315)         (10,863)         (12,073)           Inter-segment         96         176         626         898         888 <td>Segment cost of sales</td> <td>-</td> <td>(465)</td> <td>(81,019)</td> <td>(81,484)</td>	Segment cost of sales	-	(465)	(81,019)	(81,484)
Gross (loss)/profit         -         (187)         28,358         28,201           Other income including finance income         595         182         668         1,445           Inter-segment         (46)         (4)         (313)         (363)           External other income         549         178         355         1,082           Other expenses including finance costs         (745)         (315)         (10,863)         (12,073)           Inter-segment         96         176         626         898           External other expenses         (649)         (139)         (10,237)         (11,175)           Operating (loss)/profit before tax         (100)         (148)         18,506         18,258           Change in fair value of biological assets         -         -         (4,977)         (4,977)	Inter-segment cost of sales	-	45	9	54
Other income including finance income         595         182         668         1,445           Inter-segment         (46)         (4)         (313)         (363)           External other income         549         178         355         1,082           Other expenses including finance costs         (745)         (315)         (10,863)         (12,073)           Inter-segment         96         176         626         898           External other expenses         (649)         (139)         (10,237)         (11,175)           Operating (loss)/profit before tax         (100)         (148)         18,506         18,258           Change in fair value of biological assets         -         -         (4,977)         (4,977)	External cost of sales	-	(420)	(81,010)	(81,430)
finance income       595       162       666       1,445         Inter-segment       (46)       (4)       (313)       (363)         External other income       549       178       355       1,082         Other expenses including finance costs       (745)       (315)       (10,863)       (12,073)         Inter-segment       96       176       626       898         External other expenses       (649)       (139)       (10,237)       (11,175)         Operating (loss)/profit before tax       (100)       (148)       18,506       18,258         Change in fair value of biological assets       -       -       (4,977)       (4,977)	Gross (loss)/profit	-	(187)	28,358	28,201
External other income         549         178         355         1,082           Other expenses including finance costs         (745)         (315)         (10,863)         (12,073)           Inter-segment         96         176         626         898           External other expenses         (649)         (139)         (10,237)         (11,175)           Operating (loss)/profit before tax         (100)         (148)         18,506         18,258           Change in fair value of biological assets         -         -         (4,977)         (4,977)		595	182	668	1,445
Other expenses including finance costs(745)(315)(10,863)(12,073)Inter-segment96176626898External other expenses(649)(139)(10,237)(11,175)Operating (loss)/profit before tax(100)(148)18,50618,258Change in fair value of biological assets(4,977)(4,977)	Inter-segment	(46)	(4)	(313)	(363)
finance costs       (745)       (315)       (10,863)       (12,073)         Inter-segment       96       176       626       898         External other expenses       (649)       (139)       (10,237)       (11,175)         Operating (loss)/profit before tax       (100)       (148)       18,506       18,258         Change in fair value of biological assets       -       -       (4,977)       (4,977)	External other income	549	178	355	1,082
External other expenses         (649)         (139)         (10,237)         (11,175)           Operating (loss)/profit before tax         (100)         (148)         18,506         18,258           Change in fair value of biological assets         -         -         (4,977)         (4,977)		(745)	(315)	(10,863)	(12,073)
Operating (loss)/profit before tax(100)(148)18,50618,258Change in fair value of biological assets(4,977)(4,977)	Inter-segment	96	176	626	898
before tax(100)(148)18,50618,238Change in fair value of biological assets(4,977)(4,977)	External other expenses	(649)	(139)	(10,237)	(11,175)
biological assets		(100)	(148)	18,506	18,258
(Loss)/Profit before tax (100) (148) 13,529 13,281		-	-	(4,977)	(4,977)
	(Loss)/Profit before tax	(100)	(148)	13,529	13,281

The segment results for Estate and Mill operations for quarter ended 31 March 2017 were not presented as the Company changed its segment reporting in 2018.



#### A7. Segment Information (continued)

Segment assets and liabilities	
	As At End Of Current Financial Period 31/3/2018 RM'000
Segment assets:	
Investment holding	405,346
Oil palm operations	719,164
Management services/Rental	38,801
Others	44
	1,163,355
Elimination	(316,960)
Total assets	846,395
Segment liabilities:	
Investment holding	10,567
Oil palm operations	327,176
Management services/Rental	12,253
Others	166
	350,162
Elimination	(40,828)
Total liabilities	309,334

#### A8. Impairment of Assets

There was neither impairment loss nor reversal of such impairment loss recognised during the current interim financial period.

#### A9. Material Events Subsequent to the End of the Interim Period

There were no material events subsequent to the end of the current interim financial period that have not been reflected in the financial statements for the current interim financial period.



#### A10. Changes in the Composition of the Group

As at 31 March 2018, there were no changes in the composition of the Group arising from business combinations, acquisition or disposal of subsidiary companies and long-term investments, restructurings and discontinued operations.

#### A11. Changes in Contingent Liabilities and Contingent Assets

As at 31 March 2018, there were no material contingent liabilities or contingent assets, which upon being enforced might have a material impact on the financial position or business of the Group, except as disclosed below:

	At 31/3/2018
	RM'000
As at that date, the Company has contingent liabilities as follows:	
Corporate guarantees for banking facilities granted to a subsidiary	230,000

#### A12. Capital Expenditure Commitments

As at 31 March 2018, there were no material capital commitments for capital expenditure, contracted for or known to be contracted for by the Group which might have a material impact on the financial position or business of the Group, except as disclosed below:

	At 31/3/2018 RM'000
Contracted but not provided for	
Property, plant and equipment	19,848
Plantation development expenditure	5,425
	25,273

#### A13. Unfulfilled Contract Obligation

As at 31 March 2018, unfulfilled contract obligation of the Group is as disclosed below:

	At 31/3/2018
	RM'000
Sale Contracts	533



#### A14. Significant Related Party Transactions

The significant related party transactions during the financial period as set out below represent significant transactions with companies having common directorship or in which certain Directors or person connected to a Director have interests.

		Cumulative Quarter (3 Months)	
		Current Year - Period To Date 31/3/2018	Preceding Year - Period To Date 31/3/2017
		RM'000	RM'000
a.	KUB Sepadu Sdn. Bhd.		
	- Purchase of fresh fruit bunches	-	6,187
b.	Danawa Resources Sdn. Bhd.		
	- Rental and annual support for satellite broadband services	49	48
C.	<ul><li>Intuitive Systems Sdn. Bhd.</li><li>Software support, customisation, maintenance and implementation costs</li></ul>	15	11
d.	Stonehead sdn. Bhd.		
	- Purchase of material	68	-
e.	Ironhead Sdn. Bhd.		
	<ul> <li>Supply of bin bucket and scissor lift tipper</li> </ul>	203	-
f.	Manis Oil Sdn. Bhd.		
	- Sale of fresh fruit bunches	(1,107)	(682)
g.	Ta Ann Plywood Sdn. Bhd.		
	- Drain desiliting	52	-
h.	Ta Ann Pelita Igan Sdn. Bhd.		
	- Laboratory services	-	(6)
	- Transport services	16	-

The Directors are of the opinion that all the transactions above have been entered into in the normal course of business and they are effected on terms not materially different from those obtainable in transactions with unrelated parties.



#### A15. Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income Disclosures

	Individual Quarter (Q1)		Cumulative Quarter (3 Months)	
	Current Year Quarter 31/3/2018 RM'000	Preceding Year Corresponding Quarter 31/3/2017 (restated) RM'000	Current Year - Period To Date 31/3/2018 RM'000	Preceding Year - Period To Date 31/3/2017 (restated) RM'000
(Loss)/Profit before tax is arrived	at after charging	g:		
Depreciation of property, plant and equipment	6,028	6,057	6,028	6,057
Depreciation of plantation development expenditure	3,695	4,065	3,695	4,065
Depreciation of investment properties	42	42	42	42
Change in fair value of biological assets	-	4,977	-	4,977
Change in fair value of other investments	111	-	111	-
Inventories written off	70	-	70	-
Finance costs	1,634	1,438	1,634	1,438
(Loss)/Profit before tax is arrived	at after crediting	g:		
Dividend income from other investments	41	35	41	35
Change in fair value of other investments	-	52	-	52
Change in fair value of biological assets	2,223	-	2,223	-
Gain on disposal of other investments	9	20	9	20
Other income	538	322	538	322
Finance income	860	760	860	760

Other items not applicable to the Group are foreign exchange gain or loss and gain or loss on derivatives.



#### **B1.** Review of Performance

#### Quarter 1, 2018 vs Quarter 1, 2017 Three months ended 31 March 2018 vs Three months ended 31 March 2017

The Group recorded revenue of RM70.9 million in the current financial period ended 31 March 2018 compared with RM109.6 million reported in the corresponding period of the preceding year. The Group's operating loss before tax was RM3.9 million for the current financial period as compared to an operating profit before tax of RM18.3 million for the corresponding period of the preceding year. The decrease in operating results was principally due to the effect of lower realised average selling prices and lower sale volumes of CPO and PK coupled with higher estate costs during the current financial period.

In accordance with MFRS 141, the Group recognised biological assets of RM26.9 million as at 31 March 2018 compared against RM24.7 million as at 31 December 2017, resulted in a gain arising from changes in fair value of the biological assets of RM2.2 million recorded in the current financial period. A loss arising from changes in fair value of biological assets of RM5.0 million was recorded in the corresponding period of the preceding year as a result of lower fair value of biological assets of RM32.2 million as at 31 March 2017 against RM37.2 million as at 31 December 2016.

As a result of the decrease in operating results and fair value changes of biological assets as explained above, the Group recorded a loss before tax of RM1.6 million for the current financial period compared against a profit before tax of RM13.3 million for the corresponding period of the preceding year.

The performance of the respective major business segments of the Group are as follows:

#### Oil palm operations

The oil palm operations comprise estate and mill operations. During the current financial period, estate operations recorded a revenue and loss of RM21.6 million and RM1.3 million respectively, whereas mill operations recorded a revenue and profit of RM68.4 million and RM2 million.

For the current financial period, the oil palm operations segment contributed 99.8% of the Group revenue of RM70.9 million.

The revenue of the oil palm operations decreased by RM38.7 million to RM70.7 million in the current financial period compared with RM109.4 million reported in the corresponding period of the preceding year. The decrease was principally attributed to the effect of lower realised average selling prices of CPO and PK and lower sales volumes of CPO and PK.

The average selling prices of CPO and PK had decreased approximately by 21.9% and 30.6% whereas the sales volumes of CPO and PK had decreased by approximately 16.9% and 12.6% respectively for the current financial period.

The operating loss before tax for the oil palm operations was RM3.5 million for the current financial period as compared to operating profit before tax of RM18.5 million for the corresponding period of the preceding year, in line with the decrease in revenue and increase in estate costs.

#### Other segments

Other segments' results for the current financial period are insignificant to the Group.



### B2. Material Changes in Profit Before Tax for the Current Quarter as compared with the Immediate Preceding Quarter

For the quarter under review, the Group recorded an operating loss before tax of RM3.9 million compared against an operating profit before tax of RM5 million (restated) (before impairment loss of RM12.9 million) in the preceding quarter. This was mainly attributed to lower revenue achieved as a result of lower realised average selling prices and sale volume.

The realised average selling price for CPO and PK had decreased approximately 7.7% and 16% respectively, whereas the sales volumes of CPO and PK had decreased approximately by 22.6% and 18.6% respectively for the current quarter.

The Group recorded a gain arising from changes in fair value of biological assets of RM2.2 million in the current quarter compared against a loss arising from changes in fair value of biological assets of RM10.3 million in the preceding quarter. In addition, impairment losses of RM12.9 million (restated) most of which relating to encumbered estates were recorded in the preceding quarter.

#### B3. Prospects for the Current Financial Year

The performance of the Group is largely dependent on the production, operation efficiency and prices of CPO and PK.

The Group's current focus is on the transformation and reform of the Group's management, strengthening and improving the standard operating procedures with the ultimate goal to achieve a better yield for the current financial year. Emphasis is placed on organisational and operational enhancement to increase productivity and production. Resources are allocated for areas that will immediately impact production and productivity.

Barring any unforeseen circumstances, the Board is confident that with these improvements in place, the Group will achieve better results in the near future.

#### B4. Profit Forecast or Profit Guarantee

Not applicable

#### B5. Taxation

	Individual Quarter (Q1)		Cumulative Quarter (3 Months)	
	Current Year Quarter 31/3/2018	Preceding Year Corresponding Quarter 31/3/2017 (restated)	Current Year - Period To Date 31/3/2018	Preceding Year - Period To Date 31/3/2017 (restated)
	RM'000	RM'000	RM'000	RM'000
Current tax expense	702	4,661	702	4,661
Deferred tax income	(556)	(1,338)	(556)	(1,338)
	146	3,323	146	3,323

The Group's effective tax rate for the financial period ended 31 March 2018 is lower than the statutory tax rate principally due to utilisation of tax allowance against taxable income and the reversal of timing difference in deferred tax liabilities.



#### **B6.** Other Investments

B7.

There was no material purchase or disposal of quoted securities for the current financial period.

The investments as at 31 March 2018 are as follows:

		At 31/3/2018
		RM'000
<u>Current</u>		
Financial assets at fair value through profit of	or loss	1,821
Deposits with original maturities exceeding	three months	7,805
		9,626
Loans and Borrowings		
		At 31/3/2018 RM'000
Non-current		
Term Loan (Term Financing - <i>i</i> )	- secured	104,885
Finance lease liabilities (Hire purchase -	)	1,266
		106,151
<u>Current</u>		
Revolving credit	- secured	27,000
Term Loan (Term Financing - <i>i</i> )	- secured	6,000
Revolving credit - <i>i</i>	- secured	4,000
Finance lease liabilities (Hire purchase -	)	2,495
		39,495
Total loans and borrowings		145,646

#### **Revolving Credit**

This revolving credit facility of RM50 million is secured by way of the Company's corporate guarantee and legal charge over certain land and buildings of a subsidiary.

The effective interest rate of revolving credit ranged from 4.96% to 5.21% per annum.

#### Revolving Credit (Revolving Credits -i)

The revolving credit facility of RM30 million is an Islamic facility under Bai' Inah contract, is secured by way of legal charge over certain land and buildings of a subsidiary and a corporate guarantee from the Company.

The Revolving Credit –*i* bears profit rate of 12% per annum, which is equivalent to effective profit rate of 0.60% per annum above the Bank's i-cost of funds.

#### Term Loan (Term Financing – i)

The term loan facility of RM150 million is an Islamic facility under Bai' Inah contract, is secured by way of legal charge over certain land and buildings of a subsidiary and a corporate guarantee from the Company. The loan is for a tenure of 8 years from the date of first drawdown in November 2014 and is repayable by 16 quarterly installments commencing 51th month after date of first drawdown of TF-*i*, which shall be on 12 February 2019.



#### **B7.** Loans and Borrowings (continued)

The Term Financing – i, bears profit rate of 12% per annum, which is equivalent to effective profit rate of 0.75% per annum above the Bank's i-cost of funds.

#### Finance lease liabilities (Hire purchase - *i*)

This finance lease liabilities are secured on property, plant and equipment under the finance lease.

Finance lease liabilities (Islamic) carry profit rates ranged between 4.73% - 5.22% per annum.

The above borrowings are denominated in Ringgit Malaysia.

#### **B8.** Corporate Proposals

#### Status of Corporate Proposals Announced

There was no corporate proposal being announced during the current interim financial period.

#### B9. Gains/Losses from Fair Value Changes of Financial Liabilities

There were no gains/losses arising from fair value changes of financial liabilities during the current interim financial period.

#### B10. Changes in Material Litigation

As at 9 May 2018 (being the latest practicable date which is not earlier than 7 days from the date of the issue of this quarterly report), there were no changes to the status of material litigation or arbitration in which the Company and/or any of its subsidiaries were involved either as plaintiff or defendant which has a material effect on the Group's financial position except as disclosed below:

(a) A subsidiary of the Group, SPB Pelita Suai Sdn. Bhd. ("SP Suai") sued 6 individuals ("Defendants"), seeking injunctive and declaratory relief against the Defendants for various acts of trespass over 2 parcels of Native Communal Reserve Land which the Defendants had given consent for development into an oil palm estate. SP Suai also seeks to claim damages from the Defendants.

On 18 September 2013, the learned Judge decided as follows:

- (i) There is no concluded contract between the Defendants and SP Suai;
- (ii) It has not been shown by the parties that the Defendants were members of the Penan community for which the land was gazetted for their exclusive use;
- (iii) That the gazette to allow SP Suai to deal with native land has no retrospective effect;
- (iv) Generally, parties have not proven their case against each other.

SP Suai filed a Notice of Appeal against the whole of the learned Judge's decision on 14 October 2013. The Defendants also filed a Notice of Appeal against the whole of the learned Judge's decision on the same date. SP Suai had filed and served the Record of Appeal on 2 December 2013. The Court of Appeal heard the appeal on 10 December 2015, and ordered that the case be remitted back to the High Court (before a different Judge) for a retrial. They were of the view that there was a mistrial in respect of the High Court's finding. There was no order as to costs.

The retrial of the case proceeded on 26 July 2016.

At the conclusion of the proceedings, the Court directed as follows:

- (1) The parties are to file and exchange Written Submissions;
- (2) Thereafter, the parties are to file Written Reply; and
- (3) Counsels for the parties are to appear before the Court to go through their Submissions on 25 August 2016



#### B10. Changes in Material Litigation (continued)

The Court allowed the Counsel for the Defendants' application for an extension of 2 weeks from 27 October 2016 to file the Written Submission and the same has to be filed on or before 10 November 2016. Thereafter, the parties may file Reply (if any) by 17 November 2016. Hearing of the Submissions is fixed on 28 November 2016.

The Court delivered its Judgement on 23 February 2017 as follows:

- (i) Dismissed SP Suai's claim;
- (ii) Allowed part of the Defendants' claim, namely SP Suai is prohibited from entering the 2 parcels of NCR Land and SP Suai has to vacate and remove its machineries, equipments and structures existing on the Defendants' 2 parcels of NCR land.

SP Suai filed a Notice of Appeal against the whole of the learned Judge's decision on 9 March 2017 and an application for a stay of execution on 11 April 2017. The Court heard and allowed the application for a stay of execution on 9 June 2017. The Appeal came up for Case Management on 6 September 2017. The Court of Appeal fixed the hearing of the Appeal on 27 June 2018.

(b) On 13 July 2016, the Company and SPAD were served with legal proceedings. Amongst other things, the Plaintiffs seeked a declaration to the effect that they have acquired native customary rights and/or are the customary owners over land situated at/around all of the Kampung Melugu Sri Aman.

The Company and SPAD had on 20 July 2016 entered appearance. On 10 August 2016, an application to strike out the Plaintiffs' Writ and Statement of Claim was filed and served the Plaintiffs. On 17 October 2016, the Court dismissed SPAD's application to strike out the Plaintiff's Statement of Claim. SPAD filed its appeal against the Court's said decision on 9 November 2016.

On 14 July 2017, the Court Appeal dismissed the Company and SPAD's appeal with costs in the cause.

On 18 July 2017, the parties informed the Court of the verdict of the appeal hearing. The Company and SPAD also informed the Court of their intention to amend the 'Defence of the 1<sup>st</sup> and 2<sup>nd</sup> Defendants'.

The Court fixed 18 August 2017 as the next mention date to monitor the progress of the application for amendment of the Defence of the 1<sup>st</sup> and 2<sup>nd</sup> Defendants.

On 28 August 2017, the Court had allowed the 1<sup>st</sup> and 2<sup>nd</sup> Defendants' application for amendment of the Defence. The Court on 20 September 2017 had given directions for the parties to file the bundle of documents and documents pertinent to the trial. The Court fixed the case for trial from 21<sup>st</sup> May 2018 to 25<sup>th</sup> May 2018.

The Directors, in consultation with the Company's and SPAD's advocates, are of the opinion that the Company and SPAD have strong merits in the case.

#### B11. Dividend Declared

The Board of Directors declared a first interim, single tier dividend of 5 sen per share, totalling approximately RM14 million, in respect of the financial year ending 31 December 2018, payable to shareholders on 11 June 2018. The dividend entitlement date shall be on 31 May 2018.



#### B12. Earnings per Share

	Individual Quarter (Q1)		Cumulative Quarter (3 Months)	
	Current Year Quarter 31/3/2018 RM'000	Preceding Year Corresponding Quarter 31/3/2017 (restated) RM'000	Current Year - Period To Date 31/3/2018 RM'000	Preceding Year - Period To Date 31/3/2017 (restated) RM'000
(Loss)/Profit attributable to Owners of the Company (RM)	(1,736)	9,990	(1,736)	9,990
Weighted average number of ordinary shares in issue (unit)	279,564	279,564	279,564	279,564
Basic (loss)/earnings per share (sen)	(0.62)	3.57	(0.62)	3.57
Diluted earnings per share (sen)	N/A	N/A	N/A	N/A

#### Basic earnings per share

The calculation of basic earnings per share for the interim quarter and financial period is based on the profit attributable to owners of the Company and on the weighted average number of ordinary shares in issue less the weighted average number of treasury shares held by the Company.

#### Diluted earnings per share

The diluted earnings per share for the interim quarter and financial period were not computed as the Company does not have any potentially dilutive ordinary shares as at 31 March 2018.

#### B13. Auditors' Report on Preceding Annual Financial Statements

The auditors' report on the financial statements for the financial year ended 31 December 2017 was unqualified.

#### **B14.** Review by External Auditors

The condensed consolidated financial statements of Sarawak Plantation Berhad for the quarter ended 31 March 2018 has been reviewed by the Company's auditor in accordance with the International Standard on Review Engagements 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*".

#### B15. Authorised for Issue

The condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Board on 15 May 2018.

By Order of the Board

Company Secretary Kuching 15 May 2018